BlackRock
CRXT

BlackRock’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

BlackRock’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-323,800
Closed -$124K – 6015
2022
Q2 		$124K Buy
+323,800
New +$227K ﹤0.01% 5174

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock's CRXT Position: Q3 2022 in Review

BlackRock sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 323,800 shares — an estimated $124K sold.

BlackRock first reported a position in CRXT in Q2 2022 and held it in 1 quarter. The position peaked at $124K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • BlackRock reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • BlackRock sold 323,800 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $124K.
  • BlackRock first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • BlackRock's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $124K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.